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Regulation of peripheral vascular tone in patients
with heart failure: contribution of angiotensin II
D E Newby, N E R Goodfield, A D Flapan, N A Boon, K A A Fox, D J Webb
Abstract
Objective—To determine directly the con-
tribution of angiotensin II to basal and
sympathetically stimulated peripheral ar-
teriolar tone in patients with heart failure.
Design—Parallel group comparison.
Subjects—Nine patients with New York
Heart Association grade II–IV chronic
heart failure, and age and sex matched
controls.
Interventions—Forearm plethysmogra-
phy, lower body negative pressure, local
intra-arterial administration of losartan,
angiotensin II, and noradrenaline, and
estimation of plasma hormone concentra-
tions.
Main outcome measures—Forearm blood
flow responses, plasma hormone concen-
trations.
Results—Baseline blood pressure, heart
rate, and forearm blood flow did not differ
between patients and controls. In com-
parison with the non-infused forearm,
losartan did not aVect basal forearm
blood flow (95% confidence interval −5.5%
to +7.3%) or sympathetically stimulated
vasoconstriction in controls. However, the
mean (SEM) blood flow in patients in-
creased by 13(5)% and 26(7)% in response
to 30 and 90 µg/min of losartan respec-
tively (p < 0.001). Lower body negative
pressure caused a reduction in forearm
blood flow of 20(5)% in controls
(p = 0.008) and 13(5)% (p = 0.08) in pa-
tients (p = 0.007, controls v patients).
Blood flow at 90 µg/min of losartan corre-
lated with plasma angiotensin II concen-
tration (r = 0.77; p = 0.03). Responses to
angiotensin II and noradrenaline did not
diVer between patients and controls.
Conclusions—Losartan causes acute local
peripheral arteriolar vasodilatation in
patients with heart failure but not in
healthy control subjects. Endogenous an-
giotensin II directly contributes to basal
peripheral arteriolar tone in patients with
heart failure but does not augment sym-
pathetically stimulated peripheral vascu-
lar tone.
(Heart 1998;80:134–141)
Keywords: angiotensin II; heart failure; peripheral
vascular tone; sympathetic nervous system
Angiotensin II is a potent vasoconstrictor and
pressor peptide, playing a fundamental role in
the regulation of blood pressure and body
sodium and water under circumstances of
sodium and volume depletion.1 All the major
eVects of angiotensin II are mediated through
the angiotensin II type 1 (AT1) receptor, and
include arteriolar vasoconstriction, renal so-
dium reabsorption, and stimulation of adrenal
aldosterone production.1 Within minutes of
acute hypovolaemia, renin secretion causes
rapid generation of angiotensin II, leading to
compensatory vasoconstriction and fluid reten-
tion that serves to sustain blood pressure and
prevent circulatory collapse.2 Even at doses
insuYcient to cause vasoconstriction directly,
angiotensin II augments sympathetically medi-
ated vasoconstriction3 through a prejunctional
adrenoreceptor mediated mechanism.4 5 Thus
angiotensin II has the potential to be a major
contributor to the physiological regulation of
vascular tone and blood pressure in man.
The renin-angiotensin system also plays a
central role in the pathophysiology of heart
failure. Decreased renal perfusion secondary to
low cardiac output increases renin production,
which in turn leads to increased generation of
angiotensin II. The vasoconstrictor and salt
and water retaining properties of angiotensin II
increase cardiac work, leading to a vicious cir-
cle of worsening heart failure—hence the
rationale for using ACE inhibitor treatment in
patients with heart failure to interrupt this
damaging maladaptive response. This para-
digm has been confirmed in many clinical heart
failure studies in terms of clinical status and
exercise time,6 7 and long term eVects on mor-
bidity and mortality.8–11 However, ACE inhibi-
tors not only block the generation of angio-
tensin II from angiotensin I, but also inhibit the
degradation of other peptides such as bradyki-
nin and substance P. Thus the mechanisms
whereby ACE inhibition achieves these benefi-
cial eVects in heart failure are unclear and may
not be directly attributable to a reduction in
plasma angiotensin II concentrations.12
Systemic AT1 antagonism in patients with
heart failure causes a reduction in blood pres-
sure and systemic vascular resistance.13 14 How-
ever, when examining in vivo vascular re-
sponses in man, systemic drug administration
causes concomitant eVects on organs such as
the brain, kidney, and heart, and influences
neurohumoral reflexes through changes in sys-
temic haemodynamics. Because of these con-
founding influences, vascular responses cannot
be wholly attributed to a direct eVect of the
drug in blood vessels.15 16 In contrast, the use of
bilateral forearm blood flow measurements—
with unilateral brachial artery infusion of
vasoactive drugs at subsystemic, locally active
doses—provides a powerful and reproducible
method of directly assessing vascular responses
in vivo.15 16 This technique has been used very
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successfully to demonstrate the major contri-
bution of nitric oxide and endothelin-1 to the
maintenance of basal peripheral vascular tone
in healthy people.17 18
Previous local forearm studies assessing the
role of the renin-angiotensin system in the
maintenance of basal peripheral vascular
resistance19 20 have been confounded by the use
of antagonists, such as saralasin, with partial
agonist activity. However, losartan, a selective
AT1 receptor antagonist devoid of agonist
activity, has recently become available for clini-
cal use. The aims of our study were thus to
investigate patients with heart failure and
matched healthy controls as follows: first, to
establish the role of endogenous angiotensin II
in the maintenance of peripheral vascular tone;
second, to determine the eVect of sympatheti-
cally stimulated vasoconstriction in the pres-
ence and absence of angiotensin II antagonism;
and third, to document the peripheral vascular
responses to noradrenaline and angiotensin II.
Methods
SUBJECTS
We recruited nine patients with established
chronic heart failure of New York Heart
Association (NYHA) grade II–IV who were
taking maintenance ACE inhibitor treatment.
They had a left ventricular ejection fraction of
< 35% or echocardiographic evidence of left
ventricular impairment (shortening fraction of
< 20% or left ventricular end diastolic diam-
eter of > 5.6 cm), or both. Age and sex
matched controls were also recruited. All stud-
ies were undertaken with the approval of the
local research ethics committee and the written
informed consent of each subject.
None of the control subjects received
vasoactive or non-steroidal anti-inflammatory
drugs in the week before each phase of the
study, and all abstained from alcohol for 24
hours and from food and caVeine containing
drinks for at least nine hours before each study.
Patients were withdrawn from ACE inhibitor
treatment for five drug half lives before each of
the study days. All other concomitant drugs
were omitted on the study day. All studies were
performed in a quiet, temperature controlled
room maintained at 23.5–24.5°C.
DRUGS
Losartan (Dupont-Merck, Wilmington, USA),
noradrenaline (Levophed; Sanofi Winthrop,
Guildford, UK), and angiotensin II (Clinalfa
AG, Läufelfingen, Switzerland) were dissolved
in physiological saline and given intra-
arterially. To prevent its oxidation, noradrena-
line was dissolved in saline containing 0.1%
ascorbic acid (EvansMedical, Langhurst,UK).
Doses of losartan (30–90 µg/min) were chosen
to achieve an eVective subsystemic and locally
active concentration.21 22
INTRA-ARTERIAL ADMINISTRATION
The brachial artery of the non-dominant arm
was cannulated with a 27 gauge steel needle
(Cooper’s Needle Works, Birmingham, UK)
under 1% lignocaine (Xylocaine; Astra Phar-
maceuticals, Kings Langley, UK) local anaes-
thesia. The cannula was attached to a 16 gauge
epidural catheter (Portex, Hythe, UK) and
patency maintained by infusion of physiologi-
cal saline through a syringe pump. The total
rate of intra-arterial infusions was maintained
constant throughout all studies at 1 ml/min.
FOREARM BLOOD FLOW AND BLOOD PRESSURE
Blood flow was measured in both the infused
and non-infused forearms by venous occlusion
plethysmography using mercury-in-Silastic
strain gauges applied to the widest part of the
forearm.15 During measurement periods the
hands were excluded from the circulation by
rapid inflation of the wrist cuVs to a pressure of
220 mmHg using E20 Rapid CuV Inflators (D
E Hokanson, Washington DC, USA). Upper
arm cuVs were inflated intermittently to 40
mm Hg for 10 seconds in every 15 seconds to
achieve venous occlusion and obtain plethys-
mographic recordings. Analogue voltage out-
put from an EC-4 strain gauge plethysmograph
(D E Hokanson) was processed by a MacLab
analogue to digital converter and Chart v3.3.8
software (AD Instruments, Castle Hill, Aus-
tralia) and recorded onto a MacIntosh Classic
II computer (Apple Computers, Cupertino,
USA). Calibration was achieved using the
internal standard of the plethysmograph.
Blood pressure was monitored in the non-
infused arm at intervals throughout each study,
using a semi-automated non-invasive oscillo-
metric sphygmomanometer23 (Takeda UA 751,
Takeda Medical, Tokyo, Japan).
LOWER BODY NEGATIVE PRESSURE
Subjects were rested supine in a plastic covered
steel cage enclosing the lower body from the
waist, as described previously.3 Suction was
applied using an industrial strength vacuum
cleaner regulated by a servo control unit
(Medical Physics Department, Edinburgh,
UK) to produce a constant negative pressure of
15 mmHg.Alteration to and from atmospheric
pressure was attained within one to two
seconds.
VENOUS SAMPLING AND ASSAYS
Ten minutes before giving losartan by infusion
and 10 minutes after its completion, 30 ml of
blood was withdrawn from the non-infused
arm and 10 ml admixed with each of 1 ml of
1% disodium EDTA, 0.5 ml of 0.45%
O-phenanthroline/4.65% disodium EDTA,
and 1 ml of 1% disodium EDTA/2% sodium
metabisulphite. The samples were placed on
ice and immediately centrifuged at 2000 ×g for
15 minutes. Plasma was frozen and stored at
−80°C before assay for plasma angiotensin II,
endothelin-1, big endothelin-1, adrenaline,
and noradrenaline concentrations. Following
extraction using Bond Elut columns (Varian,
Harbor City, California, USA),24 concentra-
tion of plasma angiotensin II (Peninsula
Laboratories Europe, St Helens, UK),
endothelin-1 (Peninsula Laboratories Eu-
rope), and big endothelin-1 (Peninsula Labo-
ratories Europe) were determined by radio-
immunoassay as previously described.25 26 The
intra-assay coeYcients of variability were
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5.2%, 7.0%, and 7.2%, respectively, and the
interassay coeYcients of variability were 8.6%,
9.0%, and 9.3%, respectively. The cross
reactivities of the endothelin-1 assay were as
follows: endothelin-1 (100%), endothelin-2
(7%), endothelin-3 (7%), big endothelin-1
(10.3%), C-terminal fragment (0%), angio-
tensin I (0%), and angiotensin II (0%). The
cross reactivities of the big endothelin-1 assay
were as follows: endothelin-1 (0%),
endothelin-2 (0%), endothelin-3 (0%), big
endothelin-1 (100%), C-terminal fragment
(100%), and brain natriuretic peptide-32
(0%). Adrenaline and noradrenaline concen-
trations were determined by an electrochemi-
cal method after separation by reverse phase
high performance liquid chromatography.27
STUDY DESIGN
Subjects attended at 09:00 and rested recum-
bent throughout each study. Strain gauges and
cuVs were applied and the brachial artery of the
non-dominant arm cannulated. Measurements
of forearm blood flow were made for the last
three minutes of each infusion period unless
otherwise stated. Before participating in one of
the following protocols, saline was infused for
the first 30 minutes to allow time for equilibra-
tion, with forearm blood flow measurements
being made every 10 minutes and basal blood
flow being taken as the last of these measure-
ments.
Eight patients with heart failure and eight
matched healthy controls received saline, losar-
tan 30 µg/min, losartan 90 µg/min,21 22 and
saline, each for 13 minutes and in that order.
Forearm blood flow was measured continu-
ously for the last six minutes of each infusion,
with lower body negative pressure being
applied for the last three minutes. Following 15
minutes of further saline infusion, noradrena-
line was infused intra-arterially at doses of 20,
60, 180, and 540 pmol/min,22 each for six min-
utes. At least one week later, subjects
reattended and received incremental doses of
angiotensin II (0.1, 1, 10, and 100 pmol/min),22
each dose given into the brachial artery for six
minutes. One patient withdrew after the first
visit and was replaced.
DATA ANALYSIS AND STATISTICS
Plethysmographic data were extracted from the
chart data files and forearm blood flows were
calculated for individual venous occlusion cuV
inflations by use of a template spreadsheet
(Excel v5.0; Microsoft). Recordings from the
first 60 seconds after wrist cuV inflation were
not used because this causes reflex
vasoconstriction.15 16 Usually, the last five flow
recordings in each three minute measurement
period were calculated and averaged for each
arm. To reduce the variability of blood flow
data, the ratio of flows in the two arms was cal-
culated for each time point, in eVect using the
non-infused arm as a contemporaneous con-
trol for the infused arm.15 16 Percentage changes
in the infused forearm blood flow were
calculated15 16 as follows:
% Change in blood flow =
100 × {It/NIt − Ib/NIb} / Ib/NIb
where Ib and NIb are the infused and non-
infused forearm blood flows at baseline (time
0), respectively, and It and NIt are the infused
and non-infused forearm blood flows at a given
time point.
Data were examined by analysis of variance
(ANOVA) with repeated measures, two tailed
paired Student’s t test, and regression analysis
using Excel v5.0. All results are expressed as
mean (SEM). Significance was taken at the 5%
level.
Results
Patients had significantly higher plasma
endothelin-1 and big endothelin-1 concentra-
tions than controls (table 1), with a trend for
higher plasma angiotensin II and adrenaline
concentrations.
There were no significant diVerences in
blood pressure, heart rate, or baseline forearm
blood flows in the infused and non-infused
arms between protocols, or between patient
and control subjects. Throughout all studies
there were no significant changes in heart rate
or arterial pressure (table 2; data on file).
Except during the application of lower body
negative pressure, there were no significant
changes in blood flow in the non-infused arm.
Plasma angiotensin II concentrations did not
change significantly during the study (table 1).
In the healthy control subjects, there were no
significant changes in blood flow of the infused
forearm during infusions of saline or losartan
(fig 1). Student’s t distribution gives 95% con-
fidence intervals of −5.5% to +7.3% and
−9.7% to +6.9% for percentage changes in
forearm blood flow with 30 µg/min and 90
Table 1 Subject characteristics
Control
subjects
Patients with
heart failure
Mean (SD) age (years) 61 (4) 64 (2)
Sex (M/F) 6/3 6/3
Aetiology ischaemic heart disease – 9
NYHA grade II/III/IV – 5/3/1
Left ventricular ejection fraction (%) – 30 (2)
Echocardiography
LVEDD (cm) – 7.2 (0.5)
SF (%) – 16 (2)
Concomitant treatment
ACE inhibitor – 9
Diuretic – 9
Aspirin – 9
Nitrates – 5
â Blocker – 3
Calcium antagonist – 3
Digoxin – 2
Amiodarone – 1
Blood pressure (mm Hg)
Systolic 132 (5) 132 (9)
Diastolic 82 (5) 81 (6)
Heart rate (beats/min) 66 (3) 64 (2)
Baseline blood flow (ml/100 ml/min)
Infused 4.2 (0.7) 2.8 (0.3)*
Non-infused 3.7 (0.6) 2.6 (0.2)*
Plasma endothelin-1 (fmol/ml) 1.9 (0.3) 3.0 (0.1)†
Plasma big endothelin-1 (fmol/ml) 7.9 (2.0) 19.6 (3.5)‡
Plasma angiotensin II (fmol/ml)
Basal 3.3 (0.3) 13.3 (9.6)§
After losartan 3.3 (0.4) 9.1 (3.9)§
Plasma noradrenaline (pmol /ml) 1.6 (0.5) 1.3 (0.1)
Plasma adrenaline (pmol/ml) 0.3 (0.1) 1.3 (0.6)¶
*p = 0.11; †p = 0.005; ‡p = 0.01; §p = 0.08; ¶p = 0.16.
ACE, angiotensin converting enzyme; LVEDD, left ventricular
end diastolic dimension; NYHA, New York Heart Association;
SF, shortening fraction.
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µg/min of intra-arterial losartan, respectively.
During saline infusion, lower body negative
pressure caused a 20(5)% and a 19(4)%
reduction in the infused and non-infused fore-
arm blood flow, respectively (table 2;
p = 0.008). There were no significant diVer-
ences between the vasoconstriction induced by
the application of lower body negative pressure
in the infused and non-infused arms across the
saline and losartan infusion periods (fig 1 and
table 2).
In patients with heart failure, blood flow
increased by 13.3% (95% confidence interval
+2.3 to +24.4%) and 25.6% (+9.1 to +42.2%)
in the infused forearm with 30 µg/min and 90
µg/min of intra-arterial losartan, respectively
(p < 0.001; fig 1). The increase in blood flow at
90 µg/min of losartan correlated with the base-
line plasma angiotensin II concentration
(r = 0.77; p = 0.03). Lower body negative
pressure did not significantly reduce the blood
flow in either arm (p = 0.08) and was unaf-
fected by losartan in the infused forearm (fig 1
and table 2). The lower body negative pressure
response was significantly less than that
achieved in the control subjects (p = 0.007; fig
1 and table 2).
Angiotensin II and noradrenaline caused
dose dependent vasoconstriction in both pa-
tients and controls (p < 0.001 for all; fig 2).
There was no significant diVerence in the mag-
nitude of the vasoconstriction response to
noradrenaline or angiotensin II between pa-
tients and controls.
Discussion
We have previously shown in healthy
volunteers22 that intra-arterial losartan infusion,
at doses of 30–300 µg/min, is locally active only
and is able to reverse the vasoconstriction
caused by angiotensin II infusion at 1 pmol/min
within six minutes. This dose of angiotensin II is
Table 2 Systemic haemodynamics, forearm blood flow, and lower body negative pressure (LBNP) responses during saline
and losartan infusions
Control subjects (n = 8) Patients with heart failure (n = 8)
Saline
Losartan
30 µg/min
Losartan
90 µg/min Saline Saline
Losartan
30 µg/min
Losartan
90 µg/min Saline
Blood pressure (mm Hg)
Systolic 129 (4) 132 (4) 128 (5) 133 (4) 134 (9) 134 (9) 139 (9) 133 (9)
Diastolic 86 (4) 86 (6) 85 (3) 83 (3) 83 (6) 85 (7) 85 (6) 81 (6)
Heart rate (beats/min) 74 (3) 68 (3) 65 (4) 63 (3) 64 (2) 63 (2) 62 (2) 63 (2)
Absolute forearm blood flow (ml/100ml/min)
Non-infused arm 3.8 (0.7) 4.1 (1.0) 4.2 (1.0) 4.8 (1.2) 2.9 (0.5) 2.7 (0.3) 2.7 (0.2) 2.6 (0.2)
Infused arm 4.3 (0.8) 4.7 (1.2) 4.7 (1.2) 4.8 (1.1) 3.1 (0.5) 3.4 (0.5) 3.6 (0.4) 3.2 (0.5)*
Percentage change in
forearm blood flow 1 (2) 1 (3) −1 (4) −5 (5) 0 (2) 13 (5) 26 (7) 12 (5)†
Absolute forearm blood flow with LBNP (ml/100ml/min)
Non-infused arm 3.1 (0.6) 3.3 (0.8) 3.3 (0.8) 3.5 (0.9) 2.4 (0.3) 2.4 (0.3) 2.3 (0.2) 2.3 (0.2)
Infused arm 3.4 (0.7) 3.5 (0.9) 3.7 (1.0) 4.0 (1.2) 2.5 (0.3) 2.8 (0.4) 3.0 (0.2) 2.7 (0.3)
Percentage vasoconstriction with LBNP
Non-infused arm 19 (4) 20 (4) 21 (2) 20 (5)‡ 13 (5) 11 (4) 12 (5) 13 (3)
Infused arm 20 (5) 24 (3) 24 (4) 18 (4)‡ 14 (6) 15 (4) 15 (5) 14 (5)
*p < 0.001 (two way ANOVA: infused v non-infused); †p < 0.001 (two way ANOVA: patients v controls); ‡p = 0.008 (two way ANOVA:
basal v LBNP).
Figure 1 Absolute (non-infused arm, squares; infused arm, triangles) and percentage change in forearm blood flow
responses (circles), with intermittent application (arrows) of lower body negative pressure (LBNP), to saline and losartan
(30 and 90 µg/min) infusion in healthy control subjects (empty symbols) and patients with heart failure (filled symbols).
*p < 0.001 (one way ANOVA, v baseline saline infusion); †p = 0.008 (two way ANOVA, basal v LBNP).
7
6
40
5
30
20
–10
0
523926 362310 13
Time (min)
Age and sex matched controls
LBNP
Saline Saline Losartan 30 Losartan 90%
 C
h
an
g
e 
in
 b
lo
o
d
 f
lo
w
A
b
so
lu
te
 b
lo
o
d
 f
lo
w
(m
l/1
00
 m
l/m
in
)
0–10–20
2
3
4
10
49
† † ††
523926 362310 13
Patients with chronic heart failure
Saline Saline Losartan 30 Losartan 90
0–10–20 49
*
*
*
Angiotensin II and vessel tone in heart failure 137
suYcient to cause a comparable increase in
plasma angiotensin II to that seen in patients
with heart failure and causes a reduction in
blood flow of about 20%. In the present study,
we have shown for the first time that brachial
artery infusion of losartan causes an acute local
increase in forearm blood flow by ∼25% in
patients with heart failure. This cannot be
explained by an increased sensitivity to angio-
tensin II in these patients, given the normal
dose–response relations to angiotensin II infu-
sion. Moreover, the mean plasma angiotensin II
concentrations tended to be higher in patients
with heart failure and the maximum increase in
blood flow in the infused arm significantly
correlated with plasma angiotensin II concentra-
tions. These findings suggest that in patients
with heart failure, endogenous angiotensin II
contributes to the maintenance of basal periph-
eral vascular tone. The observed reductions in
systemic vascular resistance with oral
losartan13 14 28 would therefore appear to be
related to the direct vasodilator action of AT1
antagonism on peripheral resistance vessels.
One of the first vasodilator treatment trials in
heart failure (V-HeFT I)29 showed significant
benefit for left ventricular function and
mortality using the combination of isosorbide
dinitrate and hydralazine, but not prazosin. It
would appear, therefore, that all vasodilators
are not equal and the precise mechanisms by
which some agents, but not others, produce
benefit remain unclear. In patients with heart
failure, acute systemic AT1 antagonism and
ACE inhibition reduce systemic vascular resist-
ance and blood pressure to a similar
extent.13 14 28 However, ACE inhibition also has
the potential to cause the accumulation of
endogenous vasodilating peptides such as
bradykinin and substance P, which raises the
possibility that the resultant vasodilatation may
not be solely attributable to a reduction in
angiotensin II generation. Indeed, there is evi-
dence that endogenous bradykinin may regu-
late arteriolar tone in some vascular beds30 and
that some of the beneficial eVects of ACE inhi-
bition in heart failure may be mediated through
bradykinin.12 However, our findings of a direct
peripheral vasodilator action of losartan in
patients with heart failure suggests that the
vasodilatation induced by ACE inhibition is
also probably caused, at least in part, through a
reduction in the generation of angiotensin II.
Recently, the ELITE study31 has shown that
AT1 antagonism is associated with a lower
mortality than ACE inhibition in elderly
patients with heart failure. The mechanism of
this benefit has not been fully elucidated but
may be related to its more complete inhibition
of angiotensin II action, and peripheral and
systemic vasodilator actions may contribute.
In agreement with previous studies,32–34 we
have additionally shown an attenuation of fore-
arm vasoconstriction to lower body negative
pressure in patients with heart failure. The
mechanism of this impaired response is not a
result of a reduction in peripheral sensitivity to
noradrenaline, given the normal responsive-
ness to noradrenaline infusion in these pa-
tients.Heart failure is associated with increased
sympathetic nerve outflow35 and suggests that
the impaired response to lower body negative
pressure may reflect increased basal activity
attenuating the eVect of further stimulation of
the reflex. Alternatively, 15 mm Hg of lower
body negative pressure in patients with high
cardiac filling pressures may not be suYcient to
reduce the pressure in the atria or pulmonary
arteries to enable unloading of the cardiopul-
monary baroreceptors and stimulation of the
reflex. Finally, these observations are also in
keeping with the beneficial haemodynamic
eVects of peripheral venous pooling, which
reduces cardiac preload, thereby improving the
tension–pressure relation of the failing heart,
perhaps even leading to peripheral
vasodilatation.34
A reduced cardiac output leads to increases in
central sympathetic nerve outflow,35 circulating
noradrenaline concentrations,36 and peripheral
vascular resistance.37 It is well established that
angiotensin II facilitates release of noradrenaline
from nerve terminals in vitro.4 Even at doses
insuYcient to cause vasoconstriction directly,
angiotensin II augments sympathetically medi-
ated vasoconstriction in vivo3 through prejunc-
tional release of noradrenaline.5 Thus there is an
important potential for the renin-angiotensin
and sympathetic nervous systems to act syner-
gistically in the pathophysiology of heart failure.
If basal concentrations of tissue or plasma angio-
tensin II augment normal sympathetically medi-
ated vasoconstriction, then losartan would be
expected to reduce the response to lower body
negative pressure. Although this has been
described in sodium deplete hypertensive
patients, using the mixed antagonist and
partial agonist saralasin,20 we have not de-
tected an eVect of losartan on vasoconstriction
induced by lower body negative pressure, either
in patients with heart failure or in healthy
control subjects. However, there are some
inconsistencies in the responses to angiotensin II
Figure 2 Forearm blood flow responses to infusion of angiotensin II (squares) and
noradrenaline (circles) in healthy control subjects (empty symbols) and patients with heart
failure (filled symbols); p < 0.001 (one way ANOVA for each response).
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infusion during lower body negative
pressure3 38 39 with some workers finding facilita-
tion of prejunctional noradrenaline release only
at high plasma angiotensin II concentrations of
25–97 fmol/ml.38 Therefore, while the lack of an
eVect of losartan on the lower body negative
pressure response may not have been unex-
pected inhealthy controlswith lowplasmaangio-
tensin II concentrations, it is perhaps surprising
in patients with heart failure. Nevertheless, in
the present study we were only able to show a
trend for a reduction in blood flow with lower
body negative pressure in patients with heart
failure, so a small eVect of losartan could have
beenmissed. It also remains a possibility, though
unlikely, that the induction of prejunctional
noradrenaline release by angiotensin II is medi-
ated by a non-AT1-receptor mechanism.
We have studied patients with moderate
chronic heart failure receiving maintenance
diuretic and ACE inhibitor treatment. Given
that diuretic treatment can stimulate the renin-
angiotensin system, the acute withdrawal of
ACE inhibition may cause a rebound increase
in plasma angiotensin II. In this situation, the
response to AT1 antagonism might be expected
to be greater. However, our patient population
had only a moderate rise in plasma angiotensin
II concentrations and a normal responsiveness
to exogenous angiotensin II infusion.
We have also shown, in agreement with previ-
ous work,21 22 that intra-arterial losartan has no
eVect on basal forearm blood flow or vascular
resistance in healthy control subjects. The 95%
confidence intervals indicate that if angiotensin
II provides any contribution to basal tone in
peripheral blood vessels of healthy people then it
is rather small. It would appear, therefore, at
least in Western societies maintained on a
relatively high sodium diet,40 that angiotensin II
is implicated in tonic adaptive responses rather
than in the basal maintenance of peripheral
resistance vessel tone in healthy man.
In summary, using intra-arterial losartan
infusions, we have directly shown that angio-
tensin II makes an important contribution to
the local maintenance of basal peripheral
vascular tone in patients with heart failure but
not in healthy controls. This would suggest that
ACE inhibitors and angiotensin AT1 receptor
antagonists cause vasodilatation at least in part
through a direct action. In addition, we have
shown hyporesponsiveness to sympathetic
nervous system activation through barorecep-
tor unloading, which does not appear to be
augmented by angiotensin II.
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IMAGES IN CARDIOLOGY
Unruptured right sinus of Valsalva aneurysm
The diagnosis of sinus of Valsalva aneurysm is
usually made when acute congestive heart fail-
ure occurs following a rupture of the aneurysm
into the right ventricle or the right atrium. We
report a rare case of unruptured right sinus of
Valsalva aneurysm.
A 73 year old man was admitted to our
hospital because of progressive dyspnoea on
exertion. On examination his pulse was regular
at 84 beats/min and blood pressure 150/
46 mm Hg. To and fro murmur of Levine 2/6
grade was heard at the second right sternal
border. ECG showed left ventricular hypertro-
phy with ST-T changes, and chest radiography
showed moderate cardiomegaly (cardiotho-
racic ratio 0.74) and bilateral pleural eVusion.
Aortic regurgitation was thought to be the
cause of his congestive heart failure. However,
transoesophageal echocardiography (left)
revealed a large aneurysmal change of the right
sinus of Valsalva as well as severe aortic regur-
gitation. A protrusion of the aneurysm into the
right ventricle appeared to obstruct blood flow
to the outflow tract. A shunt flow was not
detected. Intravenous digital subtraction
angiography confirmed the diagnosis of
unruptured right sinus of Valsalva aneurysm,
demonstrating an impressive large filling
defect within the right ventricle (right).
(LA, left atrium; LV, left ventricle; SVA,
sinus of Valsalva aneurysm; PA, pulmonary
artery.)
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